Literature DB >> 25132044

Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing.

Ryan M Gage1, Kevin V Burns, Alan J Bank.   

Abstract

AIMS: Right ventricular pacing (RVp) results in an electrocardiographic left bundle branch block pattern and can lead to heart failure. This study aimed to evaluate echocardiographic and clinical outcomes of heart failure patients with RVp upgraded to cardiac resynchronization therapy (CRT), as they are frequently excluded from multicentre studies. METHODS AND
RESULTS: This observational study assessed 655 consecutive patients with QRS ≥120 ms and left ventricular ejection fraction ≤35%. There were 465 patients without significant previous RVp and 190 with RVp >40%. Echocardiograms were analysed pre-CRT and ∼ 1 year post-CRT. Death and heart failure hospitalizations were analysed using Cox regression, adjusted for baseline characteristics. The RVp patients had smaller end-systolic volume (P = 0.002), were older (P < 0.001), and had more atrial fibrillation (P < 0.001) pre-CRT. Ejection fraction and proportion of ischaemic aetiology were similar. One year following CRT implantation the ejection fraction response was greater in the RVp group (8.3 ± 9 vs. 5.8 ± 9 units, P = 0.005). The RVp patients had an adjusted 33% lower risk of death or heart failure hospitalization [hazard ratio (HR) 0.67 95% confidence interval (CI) 0.51-0.89, P = 0.005], while tending to have an adjusted lower risk of death (HR 0.73 95% CI 0.53-1.01, P = 0.055).
CONCLUSION: Despite similar ejection fraction pre-CRT, patients upgraded to CRT with previous RVp have smaller end-systolic volume and respond to CRT at least as well as, if not better than, other wide QRS heart failure patients. A greater improvement in ejection fraction and a lower risk of death or heart failure hospitalization when adjusted for baseline characteristics were seen in those with previous RVp.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  cardiac resynchronization therapy; echocardiography; heart failure; outcomes; right ventricular pacing

Mesh:

Year:  2014        PMID: 25132044     DOI: 10.1002/ejhf.143

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  5 in total

1.  Sequential radial and circumferential strain and oxidative stress assessment in dogs with tachycardia-induced cardiac dysfunction.

Authors:  Telma Mary Nakata; Naoya Matsuura; Hideki Kaji; Miki Shimizu; Ryuji Fukushima; Noboru Machida; Ryou Tanaka
Journal:  Int J Cardiovasc Imaging       Date:  2015-11-25       Impact factor: 2.357

2.  De novo implantation vs. upgrade cardiac resynchronization therapy: a systematic review and meta-analysis.

Authors:  Annamaria Kosztin; Mate Vamos; Daniel Aradi; Walter Richard Schwertner; Attila Kovacs; Klaudia Vivien Nagy; Endre Zima; Laszlo Geller; Gabor Zoltan Duray; Valentina Kutyifa; Bela Merkely
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

3.  Long-term clinical outcomes after upgrade to resynchronization therapy: A propensity score-matched analysis.

Authors:  Mariana Brandão; João Gonçalves Almeida; Paulo Fonseca; Joel Monteiro; Elisabeth Santos; Filipa Rosas; José Nogueira Ribeiro; Marco Oliveira; Helena Gonçalves; João Primo; Ricardo Fontes-Carvalho
Journal:  Heart Rhythm O2       Date:  2021-12-17

4.  Mortality and Heart Failure After Upgrade to Cardiac Resynchronization Therapy.

Authors:  Bogdan Beca; John L Sapp; Martin J Gardner; Christopher Gray; Amir AbdelWahab; Ciorsti MacIntyre; Steve Doucette; Ratika Parkash
Journal:  CJC Open       Date:  2019-03-06

5.  Echocardiographic Parameters as Predictors for the Efficiency of Resynchronization Therapy in Patients with Dilated Cardiomyopathy and HFrEF.

Authors:  Silvius-Alexandru Pescariu; Raluca Şoşdean; Cristina Tudoran; Adina Ionac; Gheorghe Nicusor Pop; Romulus Zorin Timar; Sorin Pescariu; Mariana Tudoran
Journal:  Diagnostics (Basel)       Date:  2021-12-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.